Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Association of anticoagulation initiation timing with thromboembolic composite outcome in patients with acute cerebral infarction and atrial fibrillation].

Created on 18 Nov 2026

Authors

Wenxiong Tang, Rui Li, Rui Liu, Yi Jin, Wei Wang, Zhaohui Tian, Lu Wang, Mengxi Yang

Published in

Zhonghua wei zhong bing ji jiu yi xue. Volume 38. Issue 10. Pages 941-946.

Abstract

To assess the association between anticoagulation initiation timing and 30-day thromboembolic composite outcome in patients with acute cerebral infarction and atrial fibrillation.
A two-center retrospective cohort study was conducted. A total of 654 patients with acute cerebral infarction and atrial fibrillation admitted to China-Japan Friendship Hospital and Yulin First Hospital from January 2018 to December 2024 were enrolled. Patients were divided into the early anticoagulation group (anticoagulation initiated≤48 hours after onset) and the delayed anticoagulation group (anticoagulation initiated>72 hours after onset), and all received therapeutic-dose anticoagulation. The demographic characteristics, vascular risk factors, National Institutes of Health Stroke Scale (NIHSS) score, atrial fibrillation embolism risk score (CHA2DS2-VASc score), and hemorrhage assessment score (HAS-BLED score) of patients were collected. Taking 30 days after onset as the outcome observation window, the primary outcome was a thromboembolic composite outcomes, included recurrent ischemic stroke, systemic arterial embolism, or deep venous thrombosis/pulmonary embolism, the secondary outcome was all-cause death, and the safety outcomes included hemorrhagic transformation, extracranial bleeding, major bleeding, and fatal bleeding. Multivariate Logistic regression analysis was used to identify relevant influencing factors with the 30-day thromboembolic composite outcome as the dependent variable.
A total of 654 patients with acute cerebral infarction and atrial fibrillation were enrolled, including 241 patients in the early anticoagulation group and 413 patients in the delayed anticoagulation group. Compared with the delayed anticoagulation group, the patients in the early anticoagulation group had a higher NIHSS score and a lower proportion of hypertension (both P<0.05); there were no statistically significant differences in demographic characteristics, other vascular risk factors, CHA2DS2-VASc scores, and HAS-BLED score between the two groups (all P>0.05). The incidence of 30-day thromboembolic composite outcome in the early anticoagulation group was lower than that in the delayed anticoagulation group [9.5% (23/241) vs. 15.7% (65/413), P<0.05], and the incidence of recurrent ischemic stroke was also lower than that in the delayed anticoagulation group [0.8% (2/241) vs. 5.3% (22/413), P<0.05]. There was no statistically significant difference in 30-day all-cause mortality between the two groups (P>0.05). In terms of safety, the incidence of extracranial hemorrhage in the early anticoagulation group was higher than that in the delayed anticoagulation group [6.2% (15/241) vs. 2.2% (9/413), P<0.05]; there were no statistically significant differences in the incidences of hemorrhagic transformation, major bleeding, and fatal bleeding between the two groups (all P>0.05). Multivariate Logistic regression analysis showed that early anticoagulation was associated with a lower risk of 30-day thromboembolic composite outcome [adjusted odds ratio (OR)=0.522, 95% confidence interval (95%CI) was 0.309-0.880, P=0.015], whereas, age≥75 years (adjusted OR=1.688, 95%CI was 1.015-2.805, P=0.044), NIHSS score≥8 (adjusted OR=2.359, 95%CI was 1.462-3.806, P<0.001), and higher CHA2DS2-VASc score (adjusted OR=1.219, 95%CI was 1.014-1.465, P=0.035) were associated with a higher risk of 30-day thromboembolic composite outcome.
Early anticoagulation within 48 hours after onset in patients with acute cerebral infarction and atrial fibrillation is associated with a lower risk of 30-day thromboembolic events and stroke recurrence, but a higher risk of extracranial hemorrhage.

PMID:
43045525
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement